Stefan Loren - 08 Jul 2026 Form 4/A - Amendment Insider Report for Cellectar Biosciences, Inc. (CLRB)

Reporting relationship: Consultant
Issuer ticker: CLRB
Reported as of: 08 Jul 2026
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 10 Jul 2026, 21:00:13 UTC
Original report date: 08 Jul 2026
Prior SEC filing: 18 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Chad Kolean, attorney-in-fact for Stefan Loren

Key filing fact

Stefan Loren filed Form 4/A - Amendment for Cellectar Biosciences, Inc. (CLRB) on 10 Jul 2026.

Key facts

This page summarizes Stefan Loren's Form 4/A - Amendment filing for Cellectar Biosciences, Inc. (CLRB).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Jul 2026, 21:00.

Change

Previous filing in this sequence was filed on 18 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001441500 Primary reporting owner

Loren Stefan

Relationship: Consultant
Address: C/O CELLECTAR BIOSCIENCES, INC., 100 CAMPUS DRIVE, FLORHAM PARK
Signature: /s/ Chad Kolean, attorney-in-fact for Stefan Loren
Signature date: 10 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CLRB transaction Derivative

Stock option (right to buy)

Award

Transaction value
Shares: +15,000
Change %
Price: $0.000000^*
Shares after: 15,000
Date: 08 Jul 2026
Ownership: Direct
Underlying class: Common stock
Underlying amount: 15,000
Exercise price: $2.69
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option shall vest in full on July 8, 2027, subject to the reporting person's continued service through the applicable vesting date.

SEC remarks

This Form 4 amendment is being filed solely to correct the exercise price of the stock option that was reported in the original Form 4 filed by the reporting person on July 8, 2026.